- Home
- BCTX vs MNDO Comparison
BCTX vs MNDO Comparison
Compare BCTX & MNDO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BCTX
- MNDO
- Stock Information
- Founded
- BCTX 2014
- MNDO 1995
- Country
- BCTX Canada
- MNDO Israel
- Employees
- BCTX N/A
- MNDO N/A
- Industry
- BCTX Biotechnology: Pharmaceutical Preparations
- MNDO EDP Services
- Sector
- BCTX Health Care
- MNDO Technology
- Exchange
- BCTX Nasdaq
- MNDO Nasdaq
- Market Cap
- BCTX 34.6M
- MNDO 39.9M
- IPO Year
- BCTX N/A
- MNDO 2000
- Fundamental
- Price
- BCTX $0.56
- MNDO $1.97
- Analyst Decision
- BCTX Strong Buy
- MNDO
- Analyst Count
- BCTX 1
- MNDO 0
- Target Price
- BCTX $15.00
- MNDO N/A
- AVG Volume (30 Days)
- BCTX 2.4M
- MNDO 23.2K
- Earning Date
- BCTX 12-16-2024
- MNDO 11-05-2024
- Dividend Yield
- BCTX N/A
- MNDO 12.21%
- EPS Growth
- BCTX N/A
- MNDO N/A
- EPS
- BCTX N/A
- MNDO 0.23
- Revenue
- BCTX N/A
- MNDO $21,856,000.00
- Revenue This Year
- BCTX N/A
- MNDO N/A
- Revenue Next Year
- BCTX N/A
- MNDO N/A
- P/E Ratio
- BCTX N/A
- MNDO $8.55
- Revenue Growth
- BCTX N/A
- MNDO 2.27
- 52 Week Low
- BCTX $0.46
- MNDO $1.70
- 52 Week High
- BCTX $5.97
- MNDO $2.28
- Technical
- Relative Strength Index (RSI)
- BCTX 38.43
- MNDO 46.85
- Support Level
- BCTX $0.57
- MNDO $1.95
- Resistance Level
- BCTX $0.66
- MNDO $2.02
- Average True Range (ATR)
- BCTX 0.13
- MNDO 0.04
- MACD
- BCTX -0.05
- MNDO -0.00
- Stochastic Oscillator
- BCTX 0.00
- MNDO 22.22
About BCTX BriaCell Therapeutics Corp.
BriaCell Therapeutics Corp is a clinical-stage immuno-oncology company. The group is developing an entirely new class of targeted immunotherapies to transform cancer care. Its product candidate Bria-IMT, is being evaluated in a pivotal Phase 3 combination study for metastatic breast cancer (MBC is breast cancer that has spread to other tissues). Bria-IMT is a targeted cell-based immunotherapy. The company is engaged in developing a Bria-OTS platform of personalized off-the-shelf cell-based immunotherapies. It is being evaluated in a Phase 1/2 clinical study and the treatment is initially focused on patients with breast cancer with an extension to prostate cancer, and other cancers.
About MNDO MIND C.T.I. Ltd.
MIND C.T.I. Ltd develops, manufactures, markets and implements real-time and off-line convergent billing and customer care software solutions. The company derives revenue from sale of software products and services in two operating segments namely Billing and Related Services, which derives key revenue and Messaging. The Company has three product lines: Product line A- billing and customer care solutions for service providers; Product line B - call accounting and call management solutions for enterprises; and Product line C - mobile messaging, communication, and payment solutions. Geographically, the company operates in The Americas, Europe, Asia Pacific and Africa and Israel. It earns maximum revenue from Europe.